Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acalabrutinib

FDA-approved product (capsule, oral), marketed as Calquence.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Acalabrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Acalabrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acalabrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

    NCT05643235 · start 2023-01-01

    Registered record
    Registry ID
    NCT05643235
    Conditions
    Atrial Fibrillation; Supraventricular Arrhythmia; Ventricular Arrhythmias and Cardiac Arrest; Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Interventions
    Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-01-01
    Completion
    2030-12-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Supraventricular Arrhythmia; Ventricular Arrhythmias and Cardiac Arrest; Chronic Lymphocytic Leukemia +1 more
    InterventionMedtronic LINQ-2 Insertable Cardiac Monitor (ILR)
    PhaseNot applicable
    Registry statusRecruiting

  • Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

    NCT05336812 · start 2022-09-13

    Registered record
    Registry ID
    NCT05336812
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Acalabrutinib; Obinutuzumab; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-09-13
    Completion
    2026-10-31
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionAcalabrutinib; Obinutuzumab; Venetoclax
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    NCT05057494 · start 2022-09-12

    Registered record
    Registry ID
    NCT05057494
    Conditions
    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Interventions
    Acalabrutinib; Venetoclax; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-09-12
    Completion
    2029-04-10
    Enrolment
    607

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    InterventionAcalabrutinib; Venetoclax; Obinutuzumab
    PhasePhase 3
    Registry statusActive not recruiting

  • Early Intervention With Acalabrutinib in Patients With High Risk CLL

    NCT04660045 · start 2022-05

    Registered record
    Registry ID
    NCT04660045
    Conditions
    Chronic Lymphocytic Leukemia; CLL/SLL
    Interventions
    Acalabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-05
    Completion
    2026-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; CLL/SLL
    InterventionAcalabrutinib
    PhasePhase 2
    Registry statusWithdrawn

  • MEOI and HRQoL in CLL Patients Treated With BTKis

    NCT04938141 · start 2021-10-07

    Registered record
    Registry ID
    NCT04938141
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-10-07
    Completion
    2024-09-26
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

    NCT04930536 · start 2021-07-14

    Registered record
    Registry ID
    NCT04930536
    Conditions
    Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
    Interventions
    Acalabrutinib capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-07-14
    Completion
    2023-05-02
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
    InterventionAcalabrutinib capsule
    PhasePhase 4
    Registry statusCompleted

  • Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

    NCT04604067 · start 2021-06-25

    Registered record
    Registry ID
    NCT04604067
    Conditions
    Diffuse Large B-cell Lymphoma
    Interventions
    Acalabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-06-25
    Completion
    2030-12
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-cell Lymphoma
    InterventionAcalabrutinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

    NCT04657094 · start 2021-03-16

    Registered record
    Registry ID
    NCT04657094
    Conditions
    Autoimmune Hemolytic Anemia; Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Warm Antibody Autoimmune Hemolytic Anemia
    Interventions
    Acalabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-03-16
    Completion
    2027-02-08
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutoimmune Hemolytic Anemia; Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Warm Antibody Autoimmune Hemolytic Anemia
    InterventionAcalabrutinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    NCT04484012 · start 2020-12-31

    Registered record
    Registry ID
    NCT04484012
    Conditions
    Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
    Interventions
    Acalabrutinib; CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-12-31
    Completion
    2026-09-02
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
    InterventionAcalabrutinib; CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    PhasePhase 2
    Registry statusRecruiting

  • Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

    NCT04257578 · start 2020-12-02

    Registered record
    Registry ID
    NCT04257578
    Conditions
    B-Cell Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma
    Interventions
    Acalabrutinib; Axicabtagene Ciloleucel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2020-12-02
    Completion
    2031-03-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-Cell Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma +4 more
    InterventionAcalabrutinib; Axicabtagene Ciloleucel
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

    NCT04189952 · start 2020-09-22

    Registered record
    Registry ID
    NCT04189952
    Conditions
    Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia; Marginal Zone Lymphoma
    Interventions
    Acalabrutinib; Rituximab; Ifosfamide; Carboplatin; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-09-22
    Completion
    2022-03-01
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia; Marginal Zone Lymphoma
    InterventionAcalabrutinib; Rituximab; Ifosfamide; Carboplatin +1 more
    PhasePhase 2
    Registry statusTerminated

  • Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

    NCT04346199 · start 2020-06-12

    Registered record
    Registry ID
    NCT04346199
    Conditions
    COVID-19
    Interventions
    Acalabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-06-12
    Completion
    2020-11-17
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionAcalabrutinib
    PhasePhase 2
    Registry statusCompleted

  • Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

    NCT04075292 · start 2020-01-20

    Registered record
    Registry ID
    NCT04075292
    Conditions
    Untreated Chronic Lymphocytic Leukemia
    Interventions
    Acalabrutinib; Rituximab; Chlorambucil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-01-20
    Completion
    2027-01-01
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUntreated Chronic Lymphocytic Leukemia
    InterventionAcalabrutinib; Rituximab; Chlorambucil
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

    NCT05140096 · start 2020-01-03

    Registered record
    Registry ID
    NCT05140096
    Conditions
    Healthy Volunteers
    Interventions
    Acalabrutinib; Fluconazole; Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-03
    Completion
    2020-04-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAcalabrutinib; Fluconazole; Isavuconazole
    PhasePhase 1
    Registry statusCompleted

  • A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

    NCT04115631 · start 2019-12-13

    Registered record
    Registry ID
    NCT04115631
    Conditions
    Liver Lymphoma; Mantle Cell Lymphoma
    Interventions
    Acalabrutinib; Bendamustine; Bendamustine Hydrochloride; Cytarabine; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-12-13
    Completion
    2026-12-31
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Lymphoma; Mantle Cell Lymphoma
    InterventionAcalabrutinib; Bendamustine; Bendamustine Hydrochloride; Cytarabine +1 more
    PhasePhase 2
    Registry statusActive not recruiting